Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 8:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Boston Pharmaceuticals Clear all
Completed No phase listed Observational

Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling

NCT00677508
View directory record Official record
Conditions
Constipation, Fecal Incontinence
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1 Interventional

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

NCT03780517
View directory record Official record
Conditions
Advanced Nonhaematologic Malignancies
Interventions
BOS172738
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 29, 2026, 8:37 AM EDT
Active, not recruiting Phase 4 Interventional

Investigating Dupilumab's Effect in Asthma by Genotype

NCT03694158
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

NCT01083316
View directory record Official record
Conditions
Amyloidosis
Interventions
Bortezomib, Dexamethasone, Melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 29, 2026, 8:37 AM EDT
Terminated Phase 2 Interventional Results available

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients

NCT02994784
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
Propylene Glycol-Free Melphalan Hydrochloride
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

NCT03036865
View directory record Official record
Conditions
Healthy Participants
Interventions
BOS161721, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT03977155
View directory record Official record
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
BOS-589, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 29, 2026, 8:37 AM EDT
Terminated Phase 2 Interventional

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

NCT00917826
View directory record Official record
Conditions
EBV Lymphomas, Lympho-proliferative Diseases
Interventions
Arginine Butyrate, Ganciclovir, Valganciclovir
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
3 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 31, 2011 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1 Interventional

Mycophenolate Mofetil in Systemic Sclerosis

NCT00433186
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

NCT04163263
View directory record Official record
Conditions
Moderate to Severe Acne Vulgaris
Interventions
BOS-356, Vehicle
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Fremont, California • Sanford, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 29, 2026, 8:37 AM EDT
Completed No phase listed Observational

Pyruvate Kinase Deficiency Natural History Study

NCT02053480
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Congenital Non-Spherocytic Hemolytic Anemia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
19
States / cities
Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

NCT01289912
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
RAD001, Placebo
Drug
Lead sponsor
Mustafa Sahin
Other
Eligibility
6 Years to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

IL1-TRAP, Rilonacept, in Systemic Sclerosis

NCT01538719
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
Interventions
Rilonacept, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

NCT01090921
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Daratumumab for the Treatment of Patients With AL Amyloidosis

NCT02841033
View directory record Official record
Conditions
AL Amyloidosis
Interventions
daratumumab
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1Phase 2 Interventional

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

NCT01724554
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 29, 2026, 8:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Angelman Syndrome Video Assessment (ASVA) Source Material Study

NCT05637697
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Not listed
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
1 Year and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kingston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1 Interventional

A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment

NCT01966328
View directory record Official record
Conditions
Vitreomacular Attachment, Vitreomacular Traction, Vitreomacular Adhesion
Interventions
36% Resolvine Intravitreal Injection, 9% Resolvine Intravitreal Injection
Drug
Lead sponsor
Jeffrey S Heier
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Beverly Hills, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

NCT02991807
View directory record Official record
Conditions
PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
Interventions
RAD001, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Palo Alto, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

NCT03371251
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BOS161721, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Anniston, Alabama • El Cajon, California • Los Alamitos, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

NCT02462889
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Intravitreal aflibercept injection, Placebo
Drug
Lead sponsor
Jeffrey S Heier
Other
Eligibility
Not listed
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 29, 2026, 8:37 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Longevity Genes in Founder Populations Project

NCT00707694
View directory record Official record
Conditions
Extreme Longevity
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2032
U.S. locations
2
States / cities
New York, New York • Riverdale, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 29, 2026, 8:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

NCT01813500
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Clostridium Difficile, Inflammatory Bowel Disease
Interventions
Blood and stool sample
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 29, 2026, 8:37 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma

NCT00306969
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
bexarotene, photopheresis
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2006 · Synced Sep 29, 2026, 8:37 AM EDT